

Poster presentation

Open Access

## Translational switch for long term maintenance of synaptic plasticity

Naveed Aslam\*, Yoshi Kubota and Harel Z Shouval

Address: Department of Neurobiology and Anatomy. The University of Texas, Medical School at Houston, Texas, USA

Email: Naveed Aslam\* - naslam621@yahoo.com

\* Corresponding author

from Seventeenth Annual Computational Neuroscience Meeting: CNS\*2008  
Portland, OR, USA. 19–24 July 2008

Published: 11 July 2008

BMC Neuroscience 2008, 9(Suppl 1):P102 doi:10.1186/1471-2202-9-S1-P102

This abstract is available from: <http://www.biomedcentral.com/1471-2202/9/S1/P102>

© 2008 Aslam et al; licensee BioMed Central Ltd.

### Introduction

Memory lasts a lifetime, yet the physiological substrate of memory, synaptic contacts, are composed of proteins that have much shorter lifetimes. A physiological analog of memory formation, long-term potentiation (LTP), has a late protein synthesis dependent phase (L-LTP) that can last for many hours in slices, or even days in vivo. Could the activity dependent synthesis of new proteins account for persistence of L-LTP and memory? Here, we examine the proposal that a self-sustaining regulation of translation can form a bistable switch that can persistently regulate the on-site synthesis of plasticity related proteins. We show that a  $\alpha$ CaMKII-CPEB1 molecular pair can operate as a bistable switch. Our results imply that L-LTP should produce an increase in the total amount of  $\alpha$ CaMKII at potentiated synapses. This paper also proposes an explanation for why the application of protein synthesis and  $\alpha$ CaMKII inhibitors at the induction and maintenance phases of L-LTP result in very different outcomes.


### Results

Previous experimental recordings have also shown that  $\alpha$ CaMKII activity regulates the induction of L-LTP [1,2]. However, its role in maintenance of L-LTP is not very clear [3,4]. We simulate the application of  $\alpha$ CaMKII activity inhibitors during the induction phase of L-LTP (Fig 1). We noted that outcome of  $\alpha$ CaMKII activity blocking depends on the effectiveness of the activity inhibitor. Our results show that 73% of  $\alpha$ CaMKII activity blocking during induction does not have any effect on L-LTP maintenance. However, as activity blocking levels are increased beyond 73% the L-LTP is compromised. Next we simulated the

application of activity inhibitors starting 1 hr after the induction of L-LTP. We show that complete blocking of  $\alpha$ CaMKII activity during the maintenance of L-LTP can completely abolish any increase in total  $\alpha$ CaMKII. However, our results also indicate that partial blocking of activity during maintenance has no effect on total amount of  $\alpha$ CaMKII, since blocking  $\alpha$ CaMKII activity by less than 96% of  $\alpha$ CaMKII does not lead to any significant change in total amount of  $\alpha$ CaMKII, and only inhibition above 98% completely abolishes any change in total  $\alpha$ CaMKII concentration.

### Conclusion

This model, of a translational switch relies on the self sustained regulation of translation and can support both synaptic specificity and stability.



**Figure 1**  
Blocking CaMKII activity.

**References**

1. Bliss TV, Collingridge GL: **A synaptic model of memory: long-term potentiation in the hippocampus.** *Nature* 1993, **361**:31-39.
2. Feng TP: **The involvement of PKC and multifunctional CaM kinase II of the postsynaptic neuron in induction and maintenance of long-term potentiation.** *Prog Brain Res* 1995, **105**:55-63.
3. Otmakhov N, Griffith LC, Lisman JE: **Postsynaptic inhibitors of calcium/calmodulin-dependent protein kinase type II block induction but not maintenance of pairing-induced long-term potentiation.** *J Neurosci* 1997, **17**:5357-5365.
4. Sanhueza M, McIntyre CC, Lisman JE: **Reversal of synaptic memory by Ca2+/calmodulin-dependent protein kinase II inhibitor.** *J Neurosci* 2007, **27**:5190-5199.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)